Cancer drug could supercharge malaria treatment and beat resistance
NCT ID NCT07559370
First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This study tests whether adding imatinib, a drug currently used for cancer, to the standard malaria treatment (artemether + lumefantrine) can clear the malaria parasite faster and fight drug resistance. About 1,100 adults with mild to moderate malaria will receive either the standard 3-day treatment or a 2-day combination with imatinib. Researchers will check safety, how quickly parasites disappear, and whether the infection comes back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Imatinib mesylate combined with artemether and lumefantrine
What this could lead to
If it works, this could lead to a shorter, more effective malaria treatment that also helps stop the spread of drug-resistant parasites.
What could go wrong
This is an early Phase 2 trial, so the added benefit of imatinib is not yet proven. There may be side effects from the combination, and results may not apply to all malaria patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA (PLASMODIUM FALCIPARUM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Victoria Biomedical Research Institute
RECRUITINGKisumu, 40100, Kenya
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact